Inactive Instrument

CURE Pharmaceutical Holding Corp. Stock Other OTC

CURR

US23127P1049

Valuation: CURE Pharmaceutical Holding Corp.

Market Cap	2.37M 2.07M 1.91M 1.76M 3.32M 228M 3.39M 22.82M 8.98M 112M 8.89M 8.7M 384M	P/E 2022	-0.43x	P/E 2023	-1.56x
Enterprise Value	10.6M 9.26M 8.55M 7.88M 14.85M 1.02B 15.18M 102M 40.19M 500M 39.81M 38.94M 1.72B	EV / Sales 2022	3.94x	EV / Sales 2023	3.15x
Free-Float	98.82%	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Latest news : CURE Pharmaceutical Holding Corp.

05/03/25	Avenir Wellness Solutions, Inc. Announces CEO Changes	CI
19/11/24	Avenir Wellness Solutions, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
02/10/24	CURE Pharmaceutical Appoints Raymond Watt to Board of Directors	CI
14/08/24	Avenir Wellness Solutions, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
28/06/24	Avenir Wellness Solutions, Inc. announced that it expects to receive $0.1219 million in funding	CI
30/05/24	Avenir Wellness Solutions, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/05/24	Avenir Wellness Solutions, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
17/05/24	Avenir Wellness Solutions, Inc. Auditor Raises 'Going Concern' Doubt	CI
12/01/24	Avenir Wellness Solutions, Inc. and Nancy Duitch Enters into Certain Senior Secured Promissory Note and Security Agreement	CI
04/01/24	Avenir Wellness Solutions, Inc. announced that it expects to receive $0.25 million in funding	CI
14/11/23	Avenir Wellness Solutions, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
15/08/23	Avenir Wellness Solutions, Inc. Provides Sales Guidance for the Second Half of 2023	CI
14/08/23	Avenir Wellness Solutions, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

More news

Press Releases: CURE Pharmaceutical Holding Corp.

09/10/24	Avenir Wellness : Amendment to Quarterly Report Form 10 Q/A	PU
02/10/24	CURE Pharmaceutical Appoints Raymond Watt to Board of Directors	AQ
16/08/23	Avenir Wellness Solutions Reports Second Quarter 2023 Results	AQ
01/08/23	Avenir Wellness Solutions Reports First Quarter 2023 Results with Strong Sequential and Year over Year Revenue Increases and Continued High Gross Margins	AQ
22/05/23	AVENIR WELLNESS SOLUTIONS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: CURE Pharmaceutical Holding Corp.

Manager	Title	Age	Since
Joel Bennett CEO	Chief Executive Officer	64	01/03/2025
Bhaumik Patel CTO	Chief Tech/Sci/R&D Officer	-	20/05/2019
Marian McNear SAM	Sales & Marketing	-	-

Director	Title	Age	Since
Robert Costantino BRD	Director/Board Member	67	16/08/2022
Robert Davidson CHM	Chairman	59	16/08/2022
Nancy Duitch BRD	Director/Board Member	71	23/10/2020

More insiders

Avenir Wellness Solutions, Inc. is a platform technology company. The Company develops proprietary wellness, nutraceutical, and topical delivery systems. The Company is focused on the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve wellness. Its wholly owned subsidiary, The Sera Labs, Inc. (Sera Labs), is engaged the development, production and sale of the Companyâ€™s wellness and beauty products. Sera Labs creates products that use science-backed, proprietary oral and topical formulations. The Company sells over 25 products under the brand names Seratopical, Seratopical Revolution SeraLabs, and Nutri-Stri. Sera Labs products are sold direct-to-consumer via online Website orders, including opt-in subscribe and save option, and also online and in-store at national drug, mass retailers, grocery chains and convenience stores and on Amazon.com.

Employees

Sector

Software

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CURE PHARMACEUTICAL HOLDING CORP.	+3.25%	-2.07%	-	-	90
MICROSOFT CORPORATION	-1.82%	+2.26%	-23.04%	+13.91%	2,980B
PALANTIR TECHNOLOGIES INC.	-1.53%	+4.41%	-14.03%	+660.80%	322B
CAMBRICON TECHNOLOGIES CORPORATION LIMITED	-6.93%	-14.96%	+204.60%	+786.10%	119B
CADENCE DESIGN SYSTEMS, INC.	-9.47%	-14.07%	+2.88%	+35.05%	101B
DATADOG, INC.	-1.38%	+0.45%	+80.71%	+129.40%	93.38B
SYNOPSYS, INC.	-7.85%	-13.74%	-34.76%	-16.68%	79.85B
SEA LIMITED	-2.04%	-6.38%	-37.72%	+65.84%	65.06B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-1.21%	-2.68%	+1.18%	+54.99%	44.48B
ROBLOX CORPORATION	-4.31%	-6.63%	-57.70%	+16.24%	38.67B
Average	-2.70%	-5.08%	+13.57%	+193.96%	426.94B
Weighted average by Cap.	-0.13%	+2.46%	-12.61%	+96.11%

	2022	2023
Net sales	4.9M 4.28M 3.95M 3.64M 6.86M 471M 7.01M 47.19M 18.56M 231M 18.39M 17.98M 795M	4.35M 3.8M 3.51M 3.23M 6.09M 419M 6.23M 41.9M 16.48M 205M 16.33M 15.97M 706M
Net income	-25.51M -22.29M -20.57M -18.96M -35.74M -2.46B -36.53M -246M -96.71M -1.2B -95.8M -93.7M -4.14B	-3.44M -3.01M -2.78M -2.56M -4.83M -332M -4.93M -33.2M -13.06M -162M -12.93M -12.65M -559M
Net Debt	7.12M 6.22M 5.74M 5.29M 9.97M 685M 10.19M 68.61M 26.99M 336M 26.73M 26.15M 1.16B	8.23M 7.2M 6.64M 6.12M 11.54M 793M 11.79M 79.36M 31.22M 388M 30.92M 30.24M 1.34B

CURE Pharmaceutical Holding Corp. Stock Other OTC

Stocks

CURR

US23127P1049

Software

Valuation: CURE Pharmaceutical Holding Corp.

Latest news : CURE Pharmaceutical Holding Corp.

Press Releases: CURE Pharmaceutical Holding Corp.

Quotes and Performance

Managers and Directors: CURE Pharmaceutical Holding Corp.

Other Software

Financials

Company Profile